Abstract

DEVELOPMENT OF CONTROLLED RELEASE CO-EVAPORATES OF METOCLOPRAMIDE HYDROCHLORIDE AND ITS EVALUATION IN THE FORM OF TABLETS.

Anannya Bose*, Dr. R.N. Pal and Susanta Paul

ABSTRACT

Metoclopramide hydrochloride is used to treat the gastrointestinal disorders. Frequent administration of metoclopramide hydrochloride can produce undesired side effects like decreased energy, diarrhea, dizziness, drowsiness, headache, nausea, vomiting, restlessness, malaise, trouble sleeping (insomnia). So, the aim of the present study was to formulate metoclopramide hydrochloride extended release matrix tablets by using different concentration of polymers (HPMC, Ethylcellulose, PVP, Eudragit E100) to minimize the dose size and dosing frequency of metoclopramide hydrochloride and study the in vitro release patterns of the drug. Metoclopramide hydrochloride matrix tablets were prepared by direct compression method by using various concentrations like 1%, 2% of HPMC, ethyl cellulose, PVP and Eudragit E-100 (1%, 1.5%, Eudragit E-100: Ethylcellulose). The prepared formulation batches were evaluated on the basis of weight variation, thickness, hardness, % of friability, % of drug content and in-vitro dissolution test. In-vitro dissolution test was done by using USP dissolution apparatus in phosphate buffer pH 7.2 as dissolution medium. The values of the evaluation were in acceptable range and the optimized formulas like B5- B8 containing the highest concentration of PVP, Ethylcellose, HPMC and Eudragit E-100 showed drug release within 12 hours, also the batch number B9 consisting both Eudragit E-100 and ethyl cellulose showed the sustained release action for more than 12 hours. The formulation showed highest correlation (R) value in case of Hixson-Crowell mechanism and the release kinetic study proved that the formulation showed release of metoclopramide hydrochloride form prepared matrix tablet to follow zero order kinetics.

Keywords: Metoclopramide hydrochloride, PVP, HPMC, Ethyl cellulose, Eudragit E-100, sustained release tablet.